Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer
| Autor: | H. J. de Voogt, M. De Pauw, Richard Sylvester, Jan G. M. Klijn, Fritz H. Schröder, Urs E. Studer |
|---|---|
| Přispěvatelé: | Urology, Medical Oncology |
| Rok vydání: | 1998 |
| Předmět: |
Oncology
Agonist Male medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class Urology Injections Subcutaneous Acid Phosphatase Antiandrogen Buserelin Disease-Free Survival Drug Administration Schedule Flutamide chemistry.chemical_compound Prostate cancer SDG 3 - Good Health and Well-being Internal medicine Cause of Death Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies Cyproterone Acetate Administration Intranasal Aged Pain Measurement Proportional Hazards Models Dose-Response Relationship Drug business.industry Goserelin Carcinoma Cyproterone acetate Prostatic Neoplasms Androgen Antagonists Middle Aged medicine.disease Survival Rate Treatment Outcome chemistry Disease Progression Cyproterone business Orchiectomy medicine.drug |
| Zdroj: | European Urology, 33, 152-158. Elsevier |
| ISSN: | 0302-2838 |
| Popis: | This is the final analysis of EORTC GU Group Trial 30843 in which the treatment of advanced, metastatic prostate cancer with a combination of the LHRH agonist buserelin (nasal spray) and cyproterone acetate (Androcur), either continuously of only during the first 2 weeks, was compared with orchidectomy. There was no significant difference between the three arms as far as response rate, time to progression (subjective and objective) and duration of survival are concerned. Retrospective stratification according to the most important prognostic factors did not change the conclusions. Possible reasons for the difference with trial 30853, which used the same entry criteria but compared goserelin and flutamide with orchidectomy, are discussed. Reasons for using cyproterone acetate in combination treatment are the prevention of flare of the disease after LHRH agonists only and the prevention/reduction of toxicity in the form of hot flushes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|